Company Overview of Endocyte, Inc.
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company’s products in pre-clinical development include EC2629, a folate receptor-t...
3000 Kent Avenue
West Lafayette, IN 47906
Founded in 1995
Key Executives for Endocyte, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $372.5K
Co-Founder, Chief Science Officer and Director
Total Annual Compensation: $228.1K
Chief Medical Officer
Total Annual Compensation: $349.0K
Vice President of Human Resources
Total Annual Compensation: $256.9K
Vice President of Research & Development
Total Annual Compensation: $328.9K
Compensation as of Fiscal Year 2016.
Endocyte, Inc. Key Developments
Endocyte, Inc. Announces Executive Changes
Mar 15 18
Endocyte, Inc. announced the nomination of Dawn Svoronos for election to its Board of Directors at the upcoming annual stockholders meeting. Ms. Svoronos has more than 30 years of experience in the pharmaceutical industry, including her tenure as President of Merck & Company's Europe/Canada region. Additionally, her previously held positions with Merck include President of Merck in Canada, Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos previously served on the board of Medivation Inc., where she also acted as interim Chief Commercial Officer as the company successfully marketed Xtandi® in advanced prostate cancer. She is currently Chair of the Board of Directors for Theratechnologies, Inc. and is a member of the Board of Directors at Xenon Pharmaceuticals, Inc., PTC Therapeutics, Inc., and AgNovos Healthcare Company. Following the successful repositioning of the company through the recent in-license of global rights to PSMA-617 and the anticipated initiation of a Phase 3 registration trial, the Board’s Nominating and Corporate Governance Committee has been conducting a succession planning review of the Board’s composition and tenure, including discussions with Board members about their individual plans. As part of that process, three of Endocyte’s current directors, Keith E. Brauer, Ann F. Hanham and Peter D. Meldrum, each of whom are members of Class II of the Board and whose current term expires at the company’s 2018 annual meeting of stockholders, informed the Committee that in support of Board succession plans, they would not stand for re-election at the 2018 annual meeting. Patrick Machado, a current Class II director, and Dawn Svoronos will stand for election in this class, along with Dr. Lesley Russell, currently a Class I director. Subject to her election as a Class II director, Dr. Russell will resign as a Class I director in order to balance the company’s three director classes.
Endocyte, Inc. Appoints Patrick Machado, J.D. to Board of Directors
Feb 27 18
Endocyte, Inc. announced the appointment of Patrick Machado, J.D. to its Board of Directors. Most recently, he was a co-founder, Chief Business Officer and Chief Financial Officer of Medivation, Inc., providing strong leadership in the development of XTANDI(R) and its successful commercial launch in prostate cancer. He served as a member of its Board of Directors until its acquisition by Pfizer in 2016.
Endocyte, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Announces Phase 3 VISION Trial
Feb 26 18
Endocyte, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2017. For the quarter, the company reported collaboration revenue of $12,000 against $12,000 a year ago. Loss from operations was $8,870,000 against $11,272,000 a year ago. Net loss was $8,564,000 or $0.18 per basic and diluted share against $11,065,000 or $0.26 per basic and diluted share a year ago. The lower net loss was driven by reductions in development expenses associated with discontinued programs and lower compensation expense arising from the restructuring announced last summer.
For the year, the company reported collaboration revenue of $70,000 against $70,000 a year ago. Loss from operations was $56,106,000 against $44,720,000 a year ago. Net loss was $55,064,000 or $1.25 per basic and diluted share against $43,888,000 or $1.04 per basic and diluted share a year ago.
Following a successful End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Endocyte finalized the phase 3 VISION trial design for 177Lu-PSMA-617. The trial will include two interim assessments of efficacy, which could potentially lead to an early approval for 177Lu-PSMA-617. The VISION trial is an international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 for the treatment of patients with progressive prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have received at least one novel androgen axis drug (NAAD) and at least one taxane regimen. VISION will enroll up to 750 patients with PSMA-positive scans, randomized in a 2:1 ratio to receive either 177Lu-PSMA-617 and best supportive care alone or in combination with a NAAD (physician’s choice), versus best supportive care alone or in combination with a NAAD (physician’s choice). Best supportive care alternatives are palliative in nature. Patients treated with 177Lu-PSMA-617 will receive 7.4 gigabecquerel (GBq) intravenously every six weeks for a maximum of six cycles. The trial will be stratified by the physician’s choice of using a NAAD or not, so the use of NAAD’s will be balanced between trial arms. The primary endpoint of the study will be overall survival (OS). Secondary endpoints include radiographic progression free survival, response evaluation criteria in solid tumors (RECIST) response, and time to first symptomatic skeletal event. Interim efficacy analyses of OS will be conducted at 50% and 70% of the 489 targeted events. Enrollment of the trial is expected to begin in the second quarter of 2018 and is expected to be completed in 18-24 months. The first interim assessment of OS could occur as early as the second half of 2019.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|